2018 has been a year characterised by uncertainty, but also significant leaps in research, access, and industry deals. With 2019 bringing a host of new challenges, not least of which is Brexit, Pharmafocus spoke to industry figures to ask what the past year meant, and what their projections are going forward.
Hilary Hutton-Squire, General Manager, UK and Ireland, Gilead Sciences
What would you say have been the big developments of the year?
